Neurohormonal Regulation and Improvement in Blood Glucose Control: Reduction of Insulin Requirement in Patients with a Nonpulsatile Ventricular Assist Device
DOI:
https://doi.org/10.1532/HSF98.2013323Abstract
Background: Heart failure is associated with prolonged stress and inflammation characterized by elevated levels of cortisol and circulating catecholamines. Persistent sympathetic stimulation secondary to the stress of heart failure causes an induced insulin resistance, which creates a need for higher doses of insulin to adequately manage hyperglycemia in this patient population. We hypothesized that cortisol and catecholamine levels would be elevated in end-stage heart failure patients, however, would be reduced after the implantation of a left ventricular assist device (LVAD). Insulin requirements would therefore be reduced post LVAD implant and control of diabetes improved as compared with pre-implant.
Methods: Pre- and postoperative cortisol, catecholamine, glycated hemoglobin, and blood glucose levels were evaluated retrospectively in 99 LVAD patients at a single center from January 2007 through November 2011. Serum was collected before LVAD implantation and monthly after implantation for 12 months consecutively. Results were evaluated and compared to insulin requirements, if any, before and after implant. Plasma levels were measured by ELISA.
Results: There were a total of 99 patients (81 men and 18 women). Two patients were implanted twice due to pump dysfunction. Mean age was 59 years, ± 10, with a median of 63 years. Of those patients, 64 had ischemic cardiomyopathy and 35 had dilated cardiomyopathy. The total patient years of LVAD support were 92.5 years. All patients received a continuous flow left ventricular assist device. Type II diabetes mellitus was diagnosed in 28 patients. Of those patients, 24 required daily insulin with an average dose of 45 units/day. Average preoperative glycated hemoglobin (HbA1c) levels were 6.8% with fasting blood glucose measurements of 136 mg/dL. Mean cortisol levels were measured at 24.3 ?g/dL before LVAD implantation, with mean plasma catecholamine levels of 1824 ?g/mL. Post operatively, average HbA1c levels were 5.38% with fasting blood glucose measurements of 122 mg/dL. Mean cortisol levels were measured at 10.9 ?g/dL with average plasma catecholamine levels were 815 ?g/mL. There was a significant decrease in both cortisol levels post LVAD implant (P = 0.012) as well as catecholamine levels (P = 0.044). The average insulin requirements post LVAD implant were significantly reduced to 13 units/day (P = 0.001). Six patients no longer required any insulin after implant.
Conclusion: Implantation of nonpulsatile LVADs has become a viable option for the treatment of end-stage heart failure, helping to improve patient quality of life by decreasing clinical symptoms associated with poor end-organ perfusion. Frequently, diabetes is a comorbid condition that exists among heart failure patients and with the reduction of the systemic inflammatory and stress response produced by the support of a nonpulsatile LVAD, many patients may benefit from a reduction in their blood glucose levels, as well as insulin requirements.
References
Aguilar D. 2008. Management of Type 2 Diabetes in patients with heart failure. Current treatment options in cardiovascular medicine 10:465-475.nAndraws R, Brown DL. 2007. Effect of inhibition of the renin-angiotensin system on development of Type 2 Diabetes mellitus (meta-analysis of randomized trials). Am J Cardiol 99:1006-1012.nBurnett CM, Duncan JM, Frazier OH, et al. 1993. Improved multiorgan function after prolonged univentricular support. Ann Thorac Surg 55(1):65-71; discussion 71.nButler J, Howser R, Portner PM, Pierson RN 3rd. 2005. Diabetes and outcomes after left ventricular assist device placement. J Card Fail 11(7):510-5.nChaoyang L, Ford ES, McGuire LC, Mokdad AH. 2007. Association of metabolic syndrome and insulin resistance with congestive heart failure: Findings from the Third National Health and Nutrition Examination Survey. J Epidemiol Community Health 61: 67-73.nDoehner W, von Haehling S, Anker SD. 2008. Insulin Resistance in Chronic Heart Failure [Letter to the Editor]. JACC 52(3).nEser A, Ural D, Bildirici U, Sahin T, Yilmaz I. 2011. Diabetic cardiomyopathy. Anadolu Kardiyol Derg 11: 732-7.nFang ZY, Prins JB, Marwick TH. Aug 2004. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 25(4):543-67.nFantoni C, Regoli F, Ghanem A, et al. 2008. Long-term outcome in diabetic heart failure patients treated with cardiac resynchronization therapy. Europ J of Heart Fail 10: 298-307.nFonarow GC, Heywood JT, Heidenreich PA, et al. 2007. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 153: 1021-8.nFunder JW. 2005. RALES, EPHESUS and Redox. J Steroid Biochem Mol Biol 93: 121-125.nGülmisal G, Bauersachs SF, Weismann D, et al. 2007. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation 115: 1754-1761.nHall JL, Fermin DR, Birks EJ, et al. 2011. Clinical, Molecular, and Genomic changes in response to a left ventricular assist device. JACC 57(6): 641-652.nHiroyuki T, Shinataro K, Shouji M. 2011. Oxidative stress and heart failure. Am J Physiol Heart Circ Physiol 301: H2181-H2190.nIngelsson E, Sundstrom J, Arnlov J, Zethelius B, Lind L. 2005. Insulin resistance and risk of congestive heart failure. JAMA 294: 334-341.nJames KB, McCarthy PM, Thomas JD, et al. 1995. Effect of the implantable left ventricular assist device on neuroendocrine activation in heart failure. Circulation 92(9): 191-195.nJessup M, Albert NA, Lanfear DE, et al. 2011. ACCF/AHA/HFSA 2011 Survey Results: Current Staffing Profile of Heart Failure Programs, Including Programs That Perform Heart Transplant and Mechanical Circulatory Support Device Implantation. A Report of the ACCF Heart Failure and Transplant Committee, AHA Heart Failure and Transplantation Committee, and Heart Failure Society of America. Journal of the American College of Cardiology 57(20):2115-24.nJessup M, Abraham WT, Casey DE, et al. 2009. Diagnosis and Management of Heart Failure in Adults; A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; Developed in Collaboration With the International Society for Heart and Lung Transplantation. Circulation 119(14):E391-479.nMatthews DR, Hosker JP, Rudenski AS. 1985. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.nPacker M. 1992. The Neurohormonal Hypothesis: A Theory to explain the mechanism of disease progression in heart failure. JACC 20: 248-254.nPaolisso G, De Riu S, Marrazzo G, Verza M, Varricchio M, D'Onofrio F. 1991. Insulin resistance and hyperinsulinemia in patients with chronic congestive heart failure. Metabolism 40(9):972-7.nParsonage W, Hetmanski D, Cowley A. 2001. Differentiation of the metabolic and vascular effects of insulin in insulin resistance in patients with chronic heart failure. Am J Cardiol 89(6):696-703.nPocock SJ, Wang D, Pfeffer MA, et al. 2006. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 27: 65-75.nReiss N, Kleikamp G, Tenderich G, Tschöpe D, Körfer R. Apr 2008. Diabetes mellitus and heart failure - incidence and surgical therapy options. Herz 33(3):206-10.nRongqun R, Cidlowski JA. 2010. Glucocorticoid signaling in cardiac disease. Horm Mol Biol Clin Invest 4(2): 559-564.nSlaughter MS. 2010. Long term continuous flow left ventricular assist device support and end-organ function: Prospects for destination therapy. J Card Surg 25: 490-494.nSlaughter MS, Pagani FD, Rogers JG, et al. 2011. Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. The Journal of Heart and Lung Transplantation 29 (4S): S1-S39.nSlaughter MS, Rogers JG, Milano CA, et al. 2009. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 361: 2241-2251.nSolomon SD, Dobson J, Pocock S, et al. 2007. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 116:1482-7.nStahrenberg R, Edelmann F, Mende M, et al. 2010. Association of glucose metabolism with diastolic function along the diabetic continuum. Diabetologia 53: 1331-1340.nTopkara VK, Dang NC, Martens TP, et al, Naka Y. 2005. Effect of diabetes on short- and long-term outcomes after left ventricular assist device implantation. J Heart Lung Transplant. 24(12):2048-53.nTsutsui H, Kinugawa S, Matsushima S. 2011. Oxidative stress and heart failure. Am J Physiol Heart Circ Physiol Sep 23.nUriel N, Naka Y, Colombo PC, et al. Feb 2011. Improved diabetic control in advanced heart failure patients treated with left ventricular assist devices. Eur J Heart Fail 13(2):195-9.nWatanabe S, Tamura T, Ono K, et al. 2010. Insulin-like growth factor axis (insulin-like growth factor-I//insulin-like growth factor-binding protein-3) as a prognostic predictor of heart failure: association with adiponectin. Eur J Heart Fail 12:1214-1222.nWisniacki N, Taylor W, Lye M, Wilding JPH. 2005. Insulin resistance and inflammatory activation in older patients with systolic and diastolic heart failure. Heart 91: 32-37.nYamaji M, Tsutamoto T, Kawahara C, Nishiyama K, Yamamoto T, Fujii M, Horie M. 2009. Serum cortisol as a useful predictor of cardiac events in patients with chronic heart failure: the impact of oxidative stress. Circ Heart Fail. 2(6):608-15. Epub 2009 Sep 28.nZain A, Wilson-Tang WH. 2012. Pharmacologic strategies to target oxidative stress in heart failure. Curr Heart Fail Rep 9:14-22.n
